Cancer Pharmacology and Preclinical Therapeutics Program

Program Leaders: Leroy F. Liu, PhD and Joseph R. Bertino, MD

Overall Goals:
The Cancer Pharmacology and Preclinical Therapeutics Program is a basic science Program that unites investigators with broad scientific expertise who share a strong interest in cancer pharmacology and preclinical drug development to create more effective cancer treatments.

Specific Aims:

To discover, design, and develop new anticancer agents.
To determine the mode of action of and the mechanism of resistance to anticancer agents.
To develop novel concepts and strategies for cancer treatment.

CALENDAR: Program Meetings, Lectures and other events for CINJ Members

Program Members

Program Members' Publications

Programs

Cell Death and Survival Signaling
Program Leader: Eileen White, PhD

Genomic Instability and Tumor Progression
Program Leader: Zhiyuan Shen, MD, PhD

Cancer Pharmacology and Preclinical Therapeutics
Program Leaders: Leroy F. Liu, PhD & Joseph R. Bertino, MD

Clinical Investigations
Program Leaders: Joseph Aisner, MD, & Bruce Haffty, MD

Carcinogenesis and Chemoprevention
Program Leaders: C. S. Yang, PhD & A-N Tony Kong, PhD

Cancer Prevention and Control
Program Leaders: Benjamin F. Crabtree, PhD & Sharon Manne, PhD

The Cancer Institute of New Jersey CINJ\|Contact CINJ	Robert Wood Johnson Medical School RWJMS\|Contact RWJMS\|Service Agreement	University of Medicine and Dentistry of New Jersey UMDNJ\|Contact UMDNJ
© 2011 Robert Wood Johnson Medical School, all rights reserved.